NRx Pharmaceuticals, Inc. (NRXP)
| Market Cap | 116.55M +235.9% |
| Revenue (ttm) | 2.29M |
| Net Income | -24.54M |
| EPS | -0.97 |
| Shares Out | 36.20M |
| PE Ratio | n/a |
| Forward PE | 4.08 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,484,089 |
| Open | 3.080 |
| Previous Close | 3.060 |
| Day's Range | 3.080 - 3.360 |
| 52-Week Range | 1.620 - 3.840 |
| Beta | 2.02 |
| Analysts | Strong Buy |
| Price Target | 40.40 (+1,154.66%) |
| Earnings Date | May 15, 2026 |
About NRXP
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for in... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for NRXP stock is "Strong Buy." The 12-month stock price target is $40.4, which is an increase of 1,154.66% from the latest price.
News
NRx Pharmaceuticals Q1 Earnings Call Highlights
NRx Pharmaceuticals NASDAQ: NRXP said it advanced several regulatory, manufacturing and clinical initiatives during the first quarter of 2026, including progress toward potential approval of its prese...
NRx Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw major regulatory and commercial progress, including advancing preservative-free ketamine toward FDA approval, expanding clinical operations, and acquiring new CNS assets. Net loss dropped 74% year-over-year, and $7 million was raised post-quarter.
NRx Pharmaceuticals Quarterly report: Q1 2026
NRx Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 18, 2026.
NRx Pharmaceuticals Earnings release: Q1 2026
NRx Pharmaceuticals released its Q1 2026 earnings on May 18, 2026, summarizing the period's financial results.
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update
Key highlights from the first quarter of operations under the expanded management team include the following: Anticipated FDA decision on the Company's ANDA for Preservative-Free Ketamine in Q3 2026, ...
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update
WILMINGTON, Del., May 14, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that it ...
NRx Pharmaceuticals initiated with a Buy at Lucid Capital
Lucid Capital initiated coverage of NRx Pharmaceuticals (NRXP) with a Buy rating and $49 price target The company is about to enter the $1.5B North American ketamine market with a…
NRx Pharmaceuticals gets FDA clearance to initiate NRX-101 trial
NRx Pharmaceuticals (NRXP) announced receipt of clearance from the FDA to initiate a clinical trial of NRX-101 vs. placebo in patients with depression and suicidality who are being treated with…
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality
Preliminary research suggests that D-cycloserine significantly enhances the effect of Transcranial Magnetic Stimulation (TMS) Trial is planned to be conducted at a leading US academic teaching hospita...
NRx Pharmaceuticals receives first commercial manufacturing order for ketamine
NRx Pharmaceuticals (NRXP) announced the initiation of its first commercial manufacturing order of its preservative-free ketamine product in anticipation of approval in Summer 2026. “NRx thanks its ma...
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine
Based on FDA Office of Generic Drugs guidance previously announced, NRx has transmitted an initial GMP manufacturing order to its US-based manufacturer. NRx has completed confirmatory GMP audits of ma...
NRx Pharmaceuticals gets FDA feedback on ketamine program
NRx Pharmaceuticals (NRXP) announced the receipt of a discipline review letter from the FDA Office of Generic Drugs and the completion of a meeting with leadership. The discipline review letter…
NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program
NRx has received a positive review letter (Discipline Review Letter) addressing Drug Quality requesting only “Minor” administrative changes NRx conducted a meeting with leadership of the FDA Office of...
White House shift on psychedelics positive for NRx, says D. Boral
D. Boral Capital analyst Jason Kolbert says NRx Pharmaceuticals (NRXP) is advancing a ketamine-based therapeutic strategy at a time when U.S. policy toward psychedelic drugs is “undergoing a meaningfu...
NRx Pharmaceuticals welcomes the newly-signed Executive Order
NRx Pharmaceuticals (NRXP) welcomes the newly-signed Executive Order: Accelerating Medical Treatments for Serious Mental Illness, signed by President Trump on April 18, 2026. In the Order, the Preside...
NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality
WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq:NRXP) welcomes the newly-signed Executive Order: ACCELERATING MEDICAL TREATMENTS FOR SERIOUS MENTAL ILLNESS, signed by ...
NRx Pharmaceuticals announces incorporation of NRx Defense Systems
NRx Pharmaceuticals (NRXP) announced the incorporation of NRx Defense Systems, a Florida-based research and development subsidiary, charged with development of neuroplastic treatments that combine D-c...
NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications
Dr. Dennis K. McBride, PhD (CAPT, Medical Service Corps, US Navy, Ret.
NRx Pharmaceuticals appoints Glenn Tyson chief commercial officer
NRx Pharmaceuticals (NRXP) announced the appointment of Glenn Tyson as the company’s first chief commercial officer. As NRx looks forward to the anticipated approval of its abbreviated new drug applic...
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company's first Chief Commercial Officer
WILMINGTON, Del., April 13, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a biopharmaceutical company that focuses on neuroplastic therapies for depression, PTSD, and related cond...
NRx Pharmaceuticals announces FDA labeling alignment for ketamine product
NRx Pharmaceuticals (NRXP) announced that it has received a letter from the labeling program of the FDA Office of Generic Drugs whose only comments were limited to minor formatting changes…
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx's Preservative-Free Ketamine Application
NRx has received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for NRx's preservative-free ketamine product. Labeling remains subject to final supervisory ...
Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network
SARASOTA, Fla. and PARIS, March 30, 2026 (GLOBE NEWSWIRE) -- Hope Therapeutics, Inc. (“Hope”), a subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), today announced a strategic partnership with Em...
NRx Pharmaceuticals Earnings Call Transcript: Q4 2025
2025 saw reduced losses, new revenue from clinic operations, and major progress toward drug approvals for KETAFREE, NRX-100, and NRX-101. Cash resources and cost controls are expected to support operations through 2026, with profitability targeted by year-end.
NRx Pharmaceuticals Earnings release: Q4 2025
NRx Pharmaceuticals released its Q4 2025 earnings on March 24, 2026, summarizing the period's financial results.